ライフサイエンスコーパス: chimeric antigen receptor

1 ctivity through modified T cell receptors or chimeric antigen receptors.

2 We also extend our work to the activation of chimeric antigen receptors.

3 SS or OTC enzymes, in concert with different chimeric antigen receptors.

4 be a first-generation biomimetic five-module chimeric antigen receptor ((5M)CAR).

5 Adoptive transfer of T cells that express a chimeric antigen receptor against fibroblast activation

6 We developed an anti-CAR19 idiotype chimeric antigen receptor (alphaCAR19) to specifically r

7 Cells co-expressing chimeric antigen receptors and ADRs persisted in mice an

8 the meantime, progress in the development of chimeric antigen receptors and in genome editing (includ

9 study, we have engineered an FVIII-specific chimeric antigen receptor (ANS8 CAR) using a FVIII-speci

10 in adult and pediatric patients who received chimeric antigen receptor-based adoptive T-cell immunoth

11 immunotherapy can be highly effective, but a chimeric antigen receptor (CAR) approach would provide a

12 Using the chimeric antigen receptor (CAR) approach, here we develo

13 r et al. (2016) find that costimulation by a chimeric antigen receptor (CAR) can control T cell metab

14 antitumor properties, making them attractive chimeric antigen receptor (CAR) carriers for redirected

15 of T cells to SLAMF7 through expression of a chimeric antigen receptor (CAR) derived from the huLuc63

16 The chimeric antigen receptor (CAR) directs T cells to targe

17 Adoptive immunotherapy using chimeric antigen receptor (CAR) expressing T cells targe

18 Here, we show that chimeric antigen receptor (CAR) expression during early

19 nation, immune checkpoint blockage (ICB) and chimeric antigen receptor (CAR) for T-cell-based adoptiv

20 cells (haNKs) engineered to express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of

21 f autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a promisi

22 cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive

23 cytoplasmic domain into a second-generation chimeric antigen receptor (CAR) improved antitumor activ

24 eneration 4-1BB costimulatory-molecule-based chimeric antigen receptor (CAR) in which targeting was a

25 Adoptive transfer of T cells that express a chimeric antigen receptor (CAR) is an approved immunothe

26 unotherapy retargeting T cells to CD19 via a chimeric antigen receptor (CAR) is an investigational tr

27 etically modified to express a CD19-specific chimeric antigen receptor (CAR) is effective for treatin

28 CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effe

29 While therapy with T cells engineered with a chimeric antigen receptor (CAR) or a classical T cell re

30 ive transfer of T cells with a CD19-specific chimeric antigen receptor (CAR) shows remarkable clinica

31 en seen with T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19, a dif

32 over, PTPN2 deletion in T cells expressing a chimeric antigen receptor (CAR) specific for the oncopro

33 Chimeric antigen receptor (CAR) T cell costimulation med

34 t we believe is a novel, human CD83-targeted chimeric antigen receptor (CAR) T cell for GVHD preventi

35 Chimeric antigen receptor (CAR) T cell immunotherapy has

36 tcomes during immune checkpoint blockade and chimeric antigen receptor (CAR) T cell therapeutic modal

37 Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cau

38 Although chimeric antigen receptor (CAR) T cell therapies have de

39 Autologous chimeric antigen receptor (CAR) T cell therapies targeti

40 To improve the safety of chimeric antigen receptor (CAR) T cell therapies, microm

41 ptive resistance compromises the efficacy of chimeric antigen receptor (CAR) T cell therapies, which

42 Responses of solid tumors to chimeric antigen receptor (CAR) T cell therapy are often

43 Chimeric antigen receptor (CAR) T cell therapy for B cel

44 The recent clinical success of chimeric antigen receptor (CAR) T cell therapy for B cel

45 ile effective in specific settings, adoptive chimeric antigen receptor (CAR) T cell therapy for cance

46 Chimeric antigen receptor (CAR) T cell therapy has been

47 Chimeric antigen receptor (CAR) T cell therapy has shown

48 Chimeric antigen receptor (CAR) T cell therapy has shown

49 has been re-energized by the application of chimeric antigen receptor (CAR) T cell therapy in cancer

50 The successes with chimeric antigen receptor (CAR) T cell therapy in early

51 In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated

52 Clinical response to chimeric antigen receptor (CAR) T cell therapy is correl

53 Chimeric antigen receptor (CAR) T cell therapy works by

54 ssessed the efficacy of a novel HIV-specific chimeric antigen receptor (CAR) T cell to target both HI

55 The extension of chimeric antigen receptor (CAR) T cells (CARTs) to T-ALL

56 tigated safety and efficacy of CD19-specific chimeric antigen receptor (CAR) T cells administered fol

57 B7-H3.BB.z-chimeric antigen receptor (CAR) T cells administered int

58 Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint i

59 Chimeric antigen receptor (CAR) T cells are a promising

60 Chimeric antigen receptor (CAR) T cells are an effective

61 Chimeric antigen receptor (CAR) T cells are potent drive

62 Chimeric antigen receptor (CAR) T cells can induce remis

63 Chimeric antigen receptor (CAR) T cells can produce dura

64 In this study, chimeric antigen receptor (CAR) T cells expressing EGFRv

65 With the approval of CD19-targeted chimeric antigen receptor (CAR) T cells for the treatmen

66 Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase

67 Adoptive immunotherapy utilizing chimeric antigen receptor (CAR) T cells has demonstrated

68 HIV-specific chimeric antigen receptor (CAR) T cells have been develo

69 Chimeric antigen receptor (CAR) T cells have been highly

70 Chimeric antigen receptor (CAR) T cells have been shown

71 Autologous chimeric antigen receptor (CAR) T cells have changed the

72 Chimeric antigen receptor (CAR) T cells have demonstrate

73 Chimeric antigen receptor (CAR) T cells have emerged as

74 Chimeric antigen receptor (CAR) T cells have proven that

75 nt antileukemia efficacy of CD123-redirected chimeric antigen receptor (CAR) T cells in preclinical h

76 Chimeric antigen receptor (CAR) T cells may provide the

77 Chimeric antigen receptor (CAR) T cells mediate anti-tum

78 me-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel fo

79 Success with chimeric antigen receptor (CAR) T cells offers an opport

80 A subset of patients treated with chimeric antigen receptor (CAR) T cells or bispecific T

81 Chimeric antigen receptor (CAR) T cells provide great ef

82 Chimeric antigen receptor (CAR) T cells represent a pote

83 Anti-CD19 chimeric antigen receptor (CAR) T cells showed significa

84 Activated effector human T cells and chimeric antigen receptor (CAR) T cells similarly employ

85 Chimeric antigen receptor (CAR) T cells targeting B-Cell

86 We generated chimeric antigen receptor (CAR) T cells targeting B7-H3

87 ducted the first-in-humans clinical trial of chimeric antigen receptor (CAR) T cells targeting BCMA.

88 Chimeric antigen receptor (CAR) T cells targeting CD19 a

89 Chimeric antigen receptor (CAR) T cells targeting CD19 h

90 Chimeric antigen receptor (CAR) T cells targeting CD19 m

91 Chimeric antigen receptor (CAR) T cells targeting CD19+

92 Adoptive transfer of high-affinity chimeric antigen receptor (CAR) T cells targeting hemato

93 ystem-sensitive disease, we hypothesize that chimeric antigen receptor (CAR) T cells targeting IL1 re

94 mphomas in vivo, we engineered CD19-targeted chimeric antigen receptor (CAR) T cells that produce sol

95 Here we test the therapeutic concept that chimeric antigen receptor (CAR) T cells that target sene

96 Extending the success of chimeric antigen receptor (CAR) T cells to T-cell malign

97 Chimeric antigen receptor (CAR) T cells were recently ap

98 Endowing chimeric antigen receptor (CAR) T cells with additional

99 New immune-based therapies with chimeric antigen receptor (CAR) T cells, bi-specific T c

100 Here we explored the utility of chimeric antigen receptor (CAR) T cells, expressing the

101 -TRBC immunotherapy, we developed anti-TRBC1 chimeric antigen receptor (CAR) T cells, which recognize

102 means of boosting the antitumor activity of chimeric antigen receptor (CAR) T cells.

103 to immunotherapies by co-culturing GBOs with chimeric antigen receptor (CAR) T cells.

104 the largest patient cohort treated with CD22 chimeric antigen receptor (CAR) T cells.

105 le of avidity optimization in the context of chimeric antigen receptor (CAR) T cells; however, a rigo

106 A key to the success of chimeric antigen receptor (CAR) T-cell based therapies g

107 Imaging strategies to monitor chimeric antigen receptor (CAR) T-cell biodistribution a

108 Innovations in chimeric antigen receptor (CAR) T-cell immunotherapies a

109 Although chimeric antigen receptor (CAR) T-cell immunotherapy hol

110 (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product.

111 highlight their approach toward dual-antigen chimeric antigen receptor (CAR) T-cell targeting in an e

112 rategies must be developed in order to adapt chimeric antigen receptor (CAR) T-cell therapies to trea

113 cel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved

114 Anti-CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a

115 Chimeric antigen receptor (CAR) T-cell therapy has produ

116 Chimeric antigen receptor (CAR) T-cell therapy has prove

117 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown

118 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown

119 Chimeric antigen receptor (CAR) T-cell therapy has signi

120 ion antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multip

121 evaluating a second-generation CD19-directed chimeric antigen receptor (CAR) T-cell therapy in pediat

122 Chimeric antigen receptor (CAR) T-cell therapy is an eme

123 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly

124 Chimeric antigen receptor (CAR) T-cell therapy is one of

125 Chimeric antigen receptor (CAR) T-cell therapy of B-cell

126 Chimeric antigen receptor (CAR) T-cell therapy targeting

127 Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targ

128 The chimeric antigen receptor (CAR) T-cell therapy tisagenle

129 KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have

130 iloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed e

131 tagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.

132 nces in cellular immunotherapy, particularly chimeric antigen receptor (CAR) T-cell therapy.

133 igen escape challenges faced by conventional chimeric antigen receptor (CAR) T-cell therapy.

134 nflammation in clinically relevant models of chimeric antigen receptor (CAR) T-cell-induced cytokine

135 have been genetically modified to express a chimeric antigen receptor (CAR) targeting the B cell ant

136 T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell ant

137 reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B-ce

138 and colleagues transduced human Tregs with a chimeric antigen receptor (CAR) that targets the HLA cla

139 Chimeric antigen receptor (CAR) therapy is a promising i

140 Chimeric antigen receptor (CAR) therapy targeting CD19 h

141 used the scFv fragment of antibody 237 as a chimeric antigen receptor (CAR) to mediate recognition o

142 ells engineered to co-express a GD2-specific chimeric antigen receptor (CAR) with interleukin-15 in c

143 poRm together with an anti-CD19-41BB-CD3zeta chimeric antigen receptor (CAR), while maintaining the f

144 Current cancer immunotherapies including chimeric antigen receptor (CAR)-based therapies and chec

145 veloped a system for efficient generation of chimeric antigen receptor (CAR)-engineered T cells (CAR-

146 h recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targe

147 Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells are a

148 Chimeric antigen receptor (CAR)-expressing T cells targe

149 Chimeric antigen receptor (CAR)-modified adoptive T-cell

150 mentation by highlighting the application of chimeric antigen receptor (CAR)-modified T cells in canc

151 etion chemotherapy followed by CD19-specific chimeric antigen receptor (CAR)-modified T cells is a re

152 Chimeric antigen receptor (CAR)-modified T cells targeti

153 y of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR)-modified T cells targeti

154 Adoptive immunotherapy using B-cell-targeted chimeric antigen receptor (CAR)-modified T cells to trea

155 tive T cell therapies, including those using chimeric antigen receptor (CAR)-modified T cells, to sol

156 associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunoth

157 the systemic administration of HER2-specific chimeric antigen receptor (CAR)-modified virus-specific

158 Chimeric antigen receptor (CAR)-redirected T lymphocytes

159 Chimeric antigen receptor (CAR)-T cell immunotherapy is

160 Despite the benefits of chimeric antigen receptor (CAR)-T cell therapies against

161 Chimeric antigen receptor (CAR)-T cell therapy has had u

162 Chimeric antigen receptor (CAR)-T cell therapy has shown

163 s that are loaded with tumour-specific human chimeric antigen receptor (CAR)-T cells for the treatmen

164 (2020) develop chimeric antigen receptor (CAR)-T cells targeting uPAR,

165 Chimeric antigen receptor (CAR)-T immunotherapy has yiel

166 Chimeric antigen receptor (CAR)-T-cell therapy for solid

167 using T cells that are programmed to express chimeric antigen receptors (CAR T cells) consistently pr

168 of genetically modified T cells that express chimeric antigen receptors (CAR T cells) has generated c

169 T cells expressing chimeric antigen receptors (CAR T cells) targeting human

170 Chimeric antigen receptors (CAR) are clinically translat

171 Chimeric antigen receptors (CAR) can transmit signals ak

172 Engineering chimeric antigen receptors (CAR) or T cell receptors (TC

173 were tested for function as third generation Chimeric Antigen Receptors (CAR) T cells demonstrating s

174 T cells engineered to express chimeric antigen receptors (CAR-T cells) have shown impr

175 antigen receptor T cells redirected to CD19 (chimeric antigen receptor [CAR19]) show great promise in

176 Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (T

177 Anti-CD19 chimeric antigen receptors (CARs) are artificial fusion

178 Chimeric antigen receptors (CARs) are fusion proteins in

179 Chimeric antigen receptors (CARs) are synthetic antigen

180 Chimeric antigen receptors (CARs) are synthetic receptor

181 Chimeric antigen receptors (CARs) are synthetic receptor

182 Chimeric antigen receptors (CARs) are synthetic receptor

183 Although the use of chimeric antigen receptors (CARs) based on single-chain

184 Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate potent cli

185 Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate robust res

186 ineered antibodies and T cells modified with chimeric antigen receptors (CARs) depends, among other t

187 Chimeric antigen receptors (CARs) direct tumor cell reco

188 Here, we discuss how chimeric antigen receptors (CARs) engineered to override

189 fer of T cells redirected with CD19-specific chimeric antigen receptors (CARs) for B-lineage acute ly

190 The successful use of chimeric antigen receptors (CARs) for the generation of

191 The adoptive transfer of T cells expressing chimeric antigen receptors (CARs) has demonstrated drama

192 Chimeric antigen receptors (CARs) have been used to enha

193 T cells genetically engineered to express chimeric antigen receptors (CARs) have proven - and impr

194 ol T cells engineered to permanently express chimeric antigen receptors (CARs) is a key feature to im

195 Expressing chimeric antigen receptors (CARs) on T cells is a means

196 an be re-directed to kill cancer cells using chimeric antigen receptors (CARs) or T cell receptors (T

197 T cells expressing chimeric antigen receptors (CARs) or the infusion of bis

198 Chimeric antigen receptors (CARs) redirect T cell cytoto

199 ll therapy using T cell receptors (TCRs) and chimeric antigen receptors (CARs) represents a new wave

200 T cells expressing CD19-targeting chimeric antigen receptors (CARs) reveal high efficacy i

201 ariable, and early reports of BCMA targeting chimeric antigen receptors (CARs) suggest antigen downre

202 pose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19

203 r of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has pro

204 While chimeric antigen receptors (CARs) using single-chain ant

205 T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity

206 e in the number of clinical trials employing chimeric antigen receptors (CARs), no comprehensive surv

207 T cells with genes encoding disease-specific chimeric antigen receptors (CARs), so that they can comb

208 ced with lentivirus expressing CD19-specific chimeric antigen receptors (CARs).

209 sponses (e.g., monoclonal antibodies [mAbs], chimeric antigen receptors [CARs]).

210 ically engineered to express a CD19-specific chimeric antigen receptor (CD19-CAR).

211 h therapies, including blinatumomab and CD19 chimeric antigen receptor (CD19CAR) T cells, yield high

212 ddressed these questions using a NKG2D-based chimeric antigen receptor construct (chNKG2D) in fully i

213 R-T) are genetically modified T cells with a chimeric antigen receptor directed against a specific tu

214 t characterization and proof of concept of a chimeric antigen receptor directed against IL1RAP expres

215 roaches to generalizing this strategy to any chimeric antigen receptor, enabling this simple non-huma

216 ia (CLL) patients treated with CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell i

217 or-associated cell membrane mucin MUC1 using chimeric antigen receptor-engineered human T cells.

218 Chimeric antigen receptor-engineered T cells targeting C

219 strated therapeutic utility as components of chimeric antigen receptor-engineered T cells, further co

220 th a Fas DNR and either a T cell receptor or chimeric antigen receptor exhibited enhanced persistence

221 w targeted agents with immune regulators and chimeric antigen receptor-expressing natural killer and

222 velopment such as adoptive NK cell transfer, chimeric antigen receptor-expressing NK cells (CAR-NKs),

223 itumor effects in murine T cell receptor and chimeric antigen receptor gene therapy models.

224 therapeutic modalities, and the emergence of chimeric antigen receptor macrophage cell therapy.

225 herapy followed by infusion of CD19-specific chimeric antigen receptor-modified (CAR) T cells has pro

226 ated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therap

227 ollowed by infusion of 2 x 106 CD19-directed chimeric antigen receptor-modified T (CAR-T) cells per k

228 phodepletion chemotherapy with CD19-targeted chimeric antigen receptor-modified T (CAR-T)-cell immuno

229 Initial success with chimeric antigen receptor-modified T cell therapy for re

230 ry acute lymphoblastic leukemia treated with chimeric antigen receptor-modified T cell therapy on a p

231 anagement of cytokine release syndrome after chimeric antigen receptor-modified T cell therapy.

232 All subjects received chimeric antigen receptor-modified T cell therapy.

233 Chimeric antigen receptor-modified T cells (CAR T cells)

234 s to immune checkpoint molecules or targeted chimeric antigen receptor-modified T cells (CAR-T cells)

235 Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells)

236 ata on invasive mold infections (IMIs) after chimeric antigen receptor-modified T-cell (CAR-T-cell) t

237 s, cytokine-induced memory-like NK cells and chimeric antigen receptor NK cells.

238 I sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors o

239 antibodies or T cells engineered to express chimeric antigen receptors or T-cell receptors (TCRs) ha

240 Chimeric antigen receptors redirect T cells (CAR-T) to t

241 Chimeric antigen receptor T (CAR-T) cell therapy has pro

242 Chimeric antigen receptor T (CAR-T) cell therapy is a ne

243 Chimeric antigen receptor T (CAR-T) cells have demonstra

244 Sustained persistence of chimeric antigen receptor T (CAR-T) cells is a key chara

245 ophage activation syndrome (MAS) occur after chimeric antigen receptor T cell (CAR T cell) infusion a

246 Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in

247 atopoietic cell transplant and CD19-directed chimeric antigen receptor T cell (CAR T) therapy at Memo

248 can be quantified in 2-uL serum samples from chimeric antigen receptor T cell (CAR-T cell) therapy pa

249 We cover chimeric antigen receptor T cell (CAR-T) therapy, vaccin

250 responses to specific drugs and by modeling chimeric antigen receptor T cell immunotherapy.

251 Chimeric antigen receptor T cell therapy has become an i

252 c therapeutics and immune approaches such as chimeric antigen receptor T cell therapy.

253 he use of checkpoint blockade antibodies and chimeric antigen receptor T cell therapy.

254 he setting of cytokine release syndrome with chimeric antigen receptor T cell therapy.

255 L survival and increased the efficacy of the chimeric antigen receptor T cell transfer and PD-1 inhib

256 Therapies employing chimeric antigen receptor T cells (CAR-T cells) targetin

257 Chimeric antigen receptor T cells (CAR-T) are geneticall

258 g low arginine microenvironment also impairs chimeric antigen receptor T cells (CAR-T) cell prolifera

259 antitumor immunity and limit the efficacy of chimeric antigen receptor T cells (CAR-T).

260 es for acute myeloid leukemia (AML), such as chimeric antigen receptor T cells (CAR-Ts) or antibody-d

261 les with the ability to recruit and activate chimeric antigen receptor T cells (CAR-Ts).

262 otent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumoma

263 Chimeric antigen receptor T cells are a new and exciting

264 HA2, HER2 and interleukin 13 receptor alpha2 chimeric antigen receptor T cells as an effective treatm

265 s, radioimmunoconjugates and, more recently, chimeric antigen receptor T cells could further improve

266 e B4 inhibitors in pemphigoid disorders, and chimeric antigen receptor T cells in pemphigus.

267 se cells are comparable to antibody-isolated chimeric antigen receptor T cells in proliferation, phen

268 we demonstrate that administration of these chimeric antigen receptor T cells into the cerebrospinal

269 We also show that chimeric antigen receptor T cells manufactured from thes

270 Management of inflammatory toxicities of chimeric antigen receptor T cells often requires multidi

271 or by targeting activating pathways, as with chimeric antigen receptor T cells or bispecific antibodi

272 Chimeric antigen receptor T cells redirected to CD19 (ch

273 repertoire, somewhat analogous to engineered chimeric antigen receptor T cells, but additionally inte

274 cluding immunotoxin, bispecific antibody and chimeric antigen receptor T cells.

275 trials for hematological malignancies using chimeric antigen receptor T cells.

276 ive cells when used as a targeting domain on chimeric antigen receptor T cells.

277 pproaches utilizing bispecific antibodies or chimeric antigen receptor T cells.

278 Chimeric antigen receptor T-cell (CAR T-cell) therapy ha

279 Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are a

280 ata on invasive mold infections (IMIs) after chimeric antigen receptor T-cell (CAR-T) therapy are lim

281 Chimeric antigen receptor T-cell therapies using defined

282 sing mesothelin (CRS-207, JNJ-64041757), and chimeric antigen receptor T-cell therapies.

283 gical deficits are frequently observed after chimeric antigen receptor T-cell therapy and are associa

284 ed the neurological toxicity associated with chimeric antigen receptor T-cell therapy in a consecutiv

285 The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleuce

286 specific viral infections, excess IL-18, and chimeric antigen receptor T-cell therapy.

287 treatment of cytokine storm associated with chimeric antigen receptor T-cell therapy.

288 CAR (chimeric antigen receptor) T cells (CARTs) are genetical

289 tment using immune check inhibitors and CAR (chimeric antigen receptor) T-cell therapy serve as excel

290 Chimeric Antigen Receptor-T (CAR-T) cell immunotherapy h

291 Chimeric antigen receptor-T (CAR-T) cell therapies can e

292 Chimeric antigen receptor-T cell (CAR-T) therapy has bee

293 tabolic disorders) and for the generation of chimeric antigen receptor-T cells for cancer therapy.

294 ion after treatment with tisagenlecleucel, a chimeric antigen receptor targeted against the CD19 anti

295 When equipped with epitope-defined TCRs or chimeric antigen receptors, these Lckpr-hTCL1Atg T cells

296 or example, through genetic engineering with chimeric antigen receptors.This meeting report puts pres

297 nt's own T cells with a transgene encoding a chimeric antigen receptor to identify and eliminate CD19

298 lass I-restricted T-cell receptors (TCRs) or chimeric antigen receptors to genetically modify CD8(+)

299 iated cytotoxicity and that T cells carrying chimeric antigen receptors with the antibody variable re

300 specifically tune the binding half-life of a chimeric antigen receptor without changing other binding